OncoMatch/Clinical Trials/NCT07325136
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Is NCT07325136 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BMS-986525 and Nivolumab for relapsed/refractory small cell lung cancer.
Treatment: BMS-986525 · Nivolumab — The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Prior therapy
Must have received: platinum-based chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0011 · Detroit, Michigan
- Local Institution - 0026 · Buffalo, New York
- Local Institution - 0005 · Durham, North Carolina
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify